Danone further invests in gut health and next-generation biotic research with the acquisition of The Akkermansia Company

Core Insights - Danone has announced the acquisition of The Akkermansia Company (TAC), a Belgian firm specializing in biotics, to enhance its focus on gut health and next-generation biotic research [1][2] - The acquisition aligns with Danone's Renew strategy, emphasizing science and innovation in response to rising consumer interest in health-focused products [2] Company Overview - Danone is a leading global food and beverage company with a focus on health-oriented categories, including Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition [3] - The company generated €27.4 billion in sales in 2024 and operates in over 120 markets with a workforce of more than 90,000 employees [3] - Danone aims to achieve B Corp certification globally by 2025, reflecting its commitment to sustainability and social impact [3] Research and Development - TAC developed the biotic strain Akkermansia muciniphila MucT™, which has been clinically shown to strengthen the gut barrier, reduce inflammation, and combat metabolic disorders such as obesity, diabetes, and cardiovascular disease [2] - The acquisition of TAC is a strategic move to deepen Danone's capabilities in gut health, which is a key component of its growth strategy [2]